LY4064912 Clinical Trials (2026): 1 Studies for Healthy & Overweight or Obesity
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 LY4064912 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Healthy & Overweight or Obesity) and 144 total planned enrollment. Most recent activity: NCT07152002 (Nov 2026).
LY4064912 clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
All LY4064912 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07152002 | YHAA | A Study of LY4064912 in Healthy Participants and With Overweight or Obesity | P1 | active not recruiting | 144 | Eli Lilly and Company | Aug 2025 |
LY4064912 clinical trials: frequently asked questions
- How many LY4064912 clinical trials are there?
- 1 LY4064912 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are LY4064912 clinical trials recruiting in 2026?
- No active LY4064912 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is LY4064912 being studied for?
- LY4064912 is being studied for Healthy, Overweight or Obesity. The trials are grouped by indication on this page.
- What phase is LY4064912 in?
- LY4064912 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4064912 clinical trials?
- The lead sponsor across the most LY4064912 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4064912as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: